219 related articles for article (PubMed ID: 34627187)
1. The detection of specific hypermethylated WIF1 and NPY genes in circulating DNA by crystal digital PCR™ is a powerful new tool for colorectal cancer diagnosis and screening.
Overs A; Flammang M; Hervouet E; Bermont L; Pretet JL; Christophe B; Selmani Z
BMC Cancer; 2021 Oct; 21(1):1092. PubMed ID: 34627187
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
[TBL] [Abstract][Full Text] [Related]
3. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.
Garrigou S; Perkins G; Garlan F; Normand C; Didelot A; Le Corre D; Peyvandi S; Mulot C; Niarra R; Aucouturier P; Chatellier G; Nizard P; Perez-Toralla K; Zonta E; Charpy C; Pujals A; Barau C; Bouché O; Emile JF; Pezet D; Bibeau F; Hutchison JB; Link DR; Zaanan A; Laurent-Puig P; Sobhani I; Taly V
Clin Chem; 2016 Aug; 62(8):1129-39. PubMed ID: 27251038
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.
Liu X; Fu J; Bi H; Ge A; Xia T; Liu Y; Sun H; Li D; Zhao Y
BMC Cancer; 2019 Dec; 19(1):1212. PubMed ID: 31830937
[TBL] [Abstract][Full Text] [Related]
5. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
6. Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer.
Shavali M; Moradi A; Tahmaseb M; Mohammadian K; Ganji SM
BMC Med Genomics; 2024 Apr; 17(1):117. PubMed ID: 38689296
[TBL] [Abstract][Full Text] [Related]
7. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
[No Abstract] [Full Text] [Related]
8. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
Bachet JB; Bouché O; Taieb J; Dubreuil O; Garcia ML; Meurisse A; Normand C; Gornet JM; Artru P; Louafi S; Bonnetain F; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Taly V; Blons H; Vernerey D; Laurent-Puig P
Ann Oncol; 2018 May; 29(5):1211-1219. PubMed ID: 29438522
[TBL] [Abstract][Full Text] [Related]
9. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study.
Jensen SØ; Øgaard N; Ørntoft MW; Rasmussen MH; Bramsen JB; Kristensen H; Mouritzen P; Madsen MR; Madsen AH; Sunesen KG; Iversen LH; Laurberg S; Christensen IJ; Nielsen HJ; Andersen CL
Clin Epigenetics; 2019 Nov; 11(1):158. PubMed ID: 31727158
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
11. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
12. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
13. Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patients.
Wang D; O'Rourke D; Sanchez-Garcia JF; Cai T; Scheuenpflug J; Feng Z
BMC Cancer; 2021 Jul; 21(1):797. PubMed ID: 34243735
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
15. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
[TBL] [Abstract][Full Text] [Related]
16. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.
Boeckx N; Op de Beeck K; Beyens M; Deschoolmeester V; Hermans C; De Clercq P; Garrigou S; Normand C; Monsaert E; Papadimitriou K; Laurent-Puig P; Pauwels P; Van Camp G; Taly V; Peeters M
Clin Colorectal Cancer; 2018 Jun; 17(2):e369-e379. PubMed ID: 29605591
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy.
Fleshner P; Braunstein GD; Ovsepyan G; Tonozzi TR; Kammesheidt A
Cancer Med; 2018 Jan; 7(1):167-174. PubMed ID: 29125240
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
19. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
[TBL] [Abstract][Full Text] [Related]
20. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
